Reviewer’s report

Title: Anticancer therapy within the last 30 days of life: results of an audit and re-audit cycle from an Australian regional cancer centre.

Version: 0 Date: 07 Nov 2019

Reviewer: Akira Inoue

Reviewer's report:

This is a report regarding anti-cancer therapy in end-of-life stage in single regional cancer center in Australia. Although the data is interesting, I have several concerns as below.

1. When the intervention based on initial audit results was done? I wonder results of initial audit truly effected on those of reaudit period because there was no interval between two audit period.
2. The conclusion that audit reduced the use of end-of-life chemotherapy was also doubtful, because of the possibility that chemotherapy was simply replaced with less-toxic immune therapy recently.
3. How about a proportion of patients who were still receiving anti-cancer therapy at the timing of palliative care referral both in audit and reaudit period?
4. It should be discussed that the difference of types of cancer between two audit period probably affected on types of anti-cancer treatment.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.